medRxivGenetic & Genomic MedicinePreprint
Transcriptomics-Driven Machine Learning Models Accurately Predict Chemotherapy Response in Muscle-invasive Bladder Cancer
Ariadna Acedo-TerradesiD, Alejo Rodriguez-VidaiD, Oscar BuisániD, Marta Bódalo‐TorruellaiD, Maria Gabarros, Miquel ClarósiD, Nuria Juanpere-RoderoiD, Marta LorenzoiD, Sergio Vázquez Montes de OcaiD, Alejandro Ríos-HoyoiD, Cristina CarratoiD, Tamara SanhuezaiD, Eduardo EyrasiD, Eulàlia PuigdecanetiD, Gottfrid SjödahliD, Júlia Perera‐BeliD, Lara NonelliD, Joaquim Bellmunt BiD
- Citations
- 1
Abstract
Muscle-invasive bladder cancer (MIBC) is associated with poor predictability of response to cisplatin-based neoadjuvant chemotherapy (NAC). Consequently, the benefit of NAC remains unclear for many patients due to the lack of reliable biomarkers. In order to identify biomarkers and build an integrated and accurate model to predict NAC response, we conducted a comprehensive transcriptomic and genomic profiling on 100 MIBC patient tumors. Our analysis identified 602 differentially expressed genes between responders and non responders. From these, we derived the Top10up and Top10dn gene signatures. We also identified a set of genes related to keratinization (KRT), extracellular matrix (ECM) and cell cycle regulation (CELL CYCLE REG) that were strongly associated with response. Additionally, we found a Wnt-related signature (WNT) significantly associated with non response. Genomic analysis revealed that mutations in DNAH8, DNAH6 or DNAH10 (DNAHalt) and deletions in KDM6A (KDM6Adel) correlated significantly with chemotherapy resistance. Using our comprehensive molecular analysis as a backbone, we developed different machine learning (ML) models, based on the Xgboost (XGB) approach. The transcriptomics-only model (XGB-R) matched the performance of the combined model (XGB-RW; AUC=0.85). The relative ease of sample collection for transcriptomic data, along with the external validation, make it a promising candidate for clinical translation. To ensure robustness and broader applicability, external validation in larger, more diverse cohorts is necessary. To facilitate this, our most predictive ML models have been made publicly available via GitHub. Statement of significanceWe present XGB-R, a robust validated machine-learning model using transcriptomic features to predict neoadjuvant chemotherapy response in muscle-invasive bladder cancer with high accuracy (AUC=0.85), being a candidate for clinical translation.
- organism: human
- assay: bulk RNA-seq
- research focus: differential expression
- research focus: benchmarking
- research focus: drug response / drug discovery
- approach: machine learning (classical)
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Assessing Prediction Performance of Neoadjuvant Chemotherapy Response in Bladder Cancer
Chris Cremer·bioRxiv·Sep 16, 2016
- Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-Institutional Prospective Cohort Evaluation
L. Bukavina, R. Ginwala, … P. H. Abbosh·bioRxiv·Jan 21, 2023
- Evaluation of gene expression-based predictors of lymph node metastasis in bladder cancer
Hafdís Birta Johansson, Fredrik Liedberg, … Gottfrid Sjödahl·Bladder CancerPeer-reviewed·Jun 1, 2025
- Personalized in-silico drug response prediction based on the genetic landscape of muscle-invasive bladder cancer
Friedemann Krentel, Franziska Singer, … Roland Seiler·bioRxiv·May 22, 2020
- Tumor-myeloid crosstalk drives therapy resistance in localized bladder cancer
Filipe L.F. Carvalho, Ji‐Hyun Lee, … Eliezer M. Van Allen·Cell Press BluePeer-reviewed·Aug 20, 2026
- Predicting Response to Platin Chemotherapy Agents with Biochemically-inspired Machine Learning
E. J. Mucaki, J. Z. L. Zhao, … P. K. Rogan·Signal Transduction and Targeted TherapyPeer-reviewed·Jan 11, 2019